{"editorial":{"content_id":"850033b7-3f74-4267-a8ca-7d79056a0a19","slug":"anvisa-abbvie-adc-20261023-6d9f12","content_type":"news","title":"巴西Anvisa批准AbbVie肺癌ADC疗法，客观缓解率34.6%","summary":"巴西国家卫生监督局批准AbbVie的telisotuzumabe vedotina用于治疗非鳞状非小细胞肺癌成人患者，巴西成为继美国之后第二个批准该疗法的国家。","body":"巴西国家卫生监督局（Anvisa）已批准AbbVie公司的telisotuzumabe vedotina，用于治疗非鳞状非小细胞肺癌（CPNPC）成人患者。巴西由此成为继美国之后第二个授权使用该疗法的国家。该疗法针对肿瘤局部晚期或转移性、c-Met蛋白高表达且已接受过既往治疗的患者。\n\n这一决定基于2期LUMINOSITY研究。在c-Met高表达患者中，客观缓解率为34.6%，中位缓解持续时间达9个月，中位总生存期为14.6个月。\n\ntelisotuzumabe vedotina是一种抗体药物偶联物（ADC），可识别c-Met蛋白并向表达该生物标志物的肿瘤细胞递送细胞毒性载荷，从而筛选具有特定分子特征的患者进行靶向治疗。\n\nGrupo Oncoclínicas胸科肿瘤学全国负责人兼头颈肿瘤学全国联合负责人William William表示：“肿瘤学中生物标志物的识别使我们能够朝着越来越个性化的治疗方向前进。”\n\n据巴西国家癌症研究所（Inca）估计，2026至2028三年间巴西每年新增肺癌病例35,380例；2024年该国气管、支气管和肺癌死亡人数超过3.2万。\n\n据AbbVie介绍，telisotuzumabe vedotina的临床开发还包括3期TeliMET NSCLC-01研究，该研究在既往接受过治疗的非鳞状晚期CPNPC、c-Met高表达且EGFR野生型患者中，将该疗法与多西他赛进行对比。\n\n研究中观察到的最常见不良反应包括周围神经病变、疲劳、食欲下降和周围性水肿。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","行业趋势","企业动态","br-health"],"content_level":"编辑整理","event_type":"行业趋势","audience_tags":[],"event_location":null,"verification_status":"unverified","published_at":"2026-10-23T23:03:56.453Z","display_date":"2026-10-23","source_published_at":null,"source_url":"https://panoramafarmaceutico.com.br/anvisa-aprova-terapia-da-abbvie-para-cancer-de-pulmao-avancado/","source_name":"Panorama Farmacêutico","source_language":"pt","author_name":"编辑部","risk_level":"medium","risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":["market_entry_opportunity","investment_signal"],"trend_signals":["precision_medicine_adoption","latam_market_expansion"]},"intelligence":{"intel_id":"5be8cbe7-f5b1-493a-a402-cc699568d8de","version":1,"event_type":"监管表态","event_date":null,"main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"批准该疗法上市的巴西监管机构","type":"regulator","country":"巴西","normalized_name":null},{"name":"AbbVie","role":"telisotuzumabe vedotina的开发商","type":"company","country":"其他","normalized_name":null},{"name":"telisotuzumabe vedotina","role":"获批用于非鳞状非小细胞肺癌的c-Met靶向ADC疗法","type":"product","country":"其他","normalized_name":null},{"name":"巴西","role":"继美国之后第二个批准该疗法的国家","type":"location","country":"巴西","normalized_name":null}],"main_action":"Anvisa批准AbbVie的telisotuzumabe vedotina用于非鳞状非小细胞肺癌成人患者","key_numbers":[{"unit":"%","label":"客观缓解率","value":"34.6"},{"unit":"个月","label":"中位缓解持续时间","value":"9"},{"unit":"个月","label":"中位总生存期","value":"14.6"},{"unit":"例/年","label":"巴西每年新增肺癌病例估计","value":"35,380"},{"unit":"人","label":"2024年巴西气管、支气管和肺癌死亡人数","value":">32,000"},{"unit":"个批准国","label":"批准顺位","value":"第二"}],"facts":[{"verified":false,"statement":"巴西国家卫生监督局（Anvisa）已批准AbbVie公司的telisotuzumabe vedotina，用于治疗非鳞状非小细胞肺癌成人患者。","source_excerpt":null},{"verified":false,"statement":"巴西由此成为继美国之后第二个授权使用该疗法的国家。","source_excerpt":null},{"verified":false,"statement":"该疗法针对肿瘤局部晚期或转移性、c-Met蛋白高表达且已接受过既往治疗的患者。","source_excerpt":null},{"verified":false,"statement":"该批准基于2期LUMINOSITY研究；在c-Met高表达患者中，客观缓解率为34.6%，中位缓解持续时间为9个月，中位总生存期为14.6个月。","source_excerpt":null},{"verified":false,"statement":"telisotuzumabe vedotina是一种抗体药物偶联物（ADC），可识别c-Met蛋白并向表达该生物标志物的肿瘤细胞递送细胞毒性载荷。","source_excerpt":null},{"verified":false,"statement":"巴西国家癌症研究所（Inca）估计，2026至2028三年间巴西每年新增肺癌病例35,380例；2024年该国气管、支气管和肺癌死亡人数超过3.2万。","source_excerpt":null},{"verified":false,"statement":"telisotuzumabe vedotina的临床开发还包括3期TeliMET NSCLC-01研究，该研究在既往接受过治疗的非鳞状晚期CPNPC、c-Met高表达且EGFR野生型患者中，将该疗法与多西他赛进行对比。","source_excerpt":null},{"verified":false,"statement":"研究中观察到的最常见不良反应包括周围神经病变、疲劳、食欲下降和周围性水肿。","source_excerpt":null}],"assessments":[{"statement":"该批准为c-Met高表达且经治的非鳞状非小细胞肺癌患者提供了新的靶向治疗选择。","confidence":"high","basis_fact_index":null},{"statement":"巴西成为第二个批准国，表明该ADC疗法在拉美市场具有先发准入信号。","confidence":"medium","basis_fact_index":null},{"statement":"报道未给出具体批准日期、定价、上市时间和公共医保纳入安排，商业可及性尚不明确。","confidence":"high","basis_fact_index":null},{"statement":"c-Met高表达生物标志物检测能力可能成为该疗法在巴西落地和患者筛选的关键环节。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"high","description":"跟进Anvisa官方批准决议、批准日期及产品在巴西的上市时间。"},{"target":"user","priority":"normal","description":"评估巴西c-Met检测覆盖能力和非鳞状NSCLC患者筛查路径。"},{"target":"both","priority":"normal","description":"监测AbbVie在巴西的定价、供应安排及是否寻求纳入公共或补充医保。"}],"affected_audience":["非鳞状非小细胞肺癌成人患者","c-Met高表达肺癌患者","肿瘤科医生","巴西药品准入与采购机构","ADC及肿瘤精准治疗行业参与者"],"risk_flags":["compliance_risk","regulatory_uncertainty"],"opportunity_flags":["market_entry_opportunity","investment_signal"],"trend_signals":["precision_medicine_adoption","latam_market_expansion"],"follow_up_needed":true,"follow_up_questions":["Anvisa批准的具体日期和官方决议编号是什么？","该疗法在巴西的定价、上市时间和供应安排如何？","是否计划纳入巴西公共医保（SUS）或补充医保？","巴西c-Met高表达检测的可及性和标准化程度如何？","3期TeliMET NSCLC-01研究是否已有主要结果？"],"related_topics":["Anvisa","AbbVie","telisotuzumabe vedotina","抗体药物偶联物","非小细胞肺癌","c-Met","精准肿瘤治疗","巴西药品审批"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-10-23T23:04:18.500Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-abbvie-adc-20261023-6d9f12","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-abbvie-adc-20261023-6d9f12","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-abbvie-adc-20261023-6d9f12?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-abbvie-adc-20261023-6d9f12?view=json","last_updated":"2026-10-23T23:04:18.628Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}